Abstract
Treatment with investigative apixaban, an oral factor Xa inhibitor, shows promise as add-on protection against recurrent ischemic cardiovascular events among acute coronary syndrome patients who already are on standard antiplatelet therapy, including aspirin and clopidogrel. But dose-dependent bleeding remains an unresolved problem. This article discusses the Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose-Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients with a Recent Acute Coronary Syndrome [APPRAISE-1; NCT00313300] trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
